There's more to the rheumatoid arthritis field than the Humira biosimilar race, Ablynx' Edwin Moses tells TPL

18 July 2016

The race to come up with a biosimilar version of the rheumatoid arthritis treatment Humira (adalimumab) – the world’s top-selling drug – is well and truly on.

For a group of RA patients for whom Humira is not suitable, however, of much more concern is the prospect of another treatment becoming available.

Belgian drugmaker Ablynx (Euronext Brussels: ABLX) Ablynx is focusing its efforts on that group of patients. The company has just presented positive top-line data in a Phase IIb study of its anti-IL-6R Nanobody, vobarilizumab, in patients who have moderately to severely active rheumatoid arthritis (RA) and are intolerant to methotrexate (MTX) or for whom continued MTX treatment is inappropriate.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK